Novel biomarkers (NGAL, CysC, IL-18, and KIM-1) provide a faster and more accurate diagnosis of AKI than traditional methods in various clinical settings. Additional research is required to fully incorporate these promising molecules into everyday clinical practice.
Gerasopoulos et al. (Thu,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: